Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). METHODS: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 ± 18 with IBS diagnosed by Rome III criteria and with a score ≥ 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). FINDINGS: Open-label placebo produced significantly higher mean (±SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 ± 1.0 vs. 4.0 ± 1.1, p<.001) and at 21-day endpoint (5.0 ± 1.5 vs. 3.9 ± 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). CONCLUSION: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. TRIAL REGISTRATION: ClinicalTrials.gov NCT01010191.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The number-needed-to-treat was 11 which should be compared with 4 for ‘placebo without deception,259 7 for alosetron,260 8 for linaclotide261 and 14 for tegaserod.262”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Several trials of psychological treatments for IBS have failed to show differential effects on symptoms when using attention control conditions [32,62-64], and a recent study showed that IBS patients even respond to open-label placebo [65].”
The cited source says what the claim attributes to it.
In the citing paper
“Kaptchuk and colleagues showed that an open label inactive placebo pill produced better outcomes in IBS patients compared to no treatment13.”
From Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial (2014) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Collecting and Interpreting Qualitative Materials
Denzin, N. K., & Lincoln, Y. S. (2012) · Cited by 6,094
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 1×
“Participants were adults ($18 years old) meeting the Rome III criteria for IBS [17] with a score of $150 on the IBS Symptom Severity Scale (IBS-SSS).”
MethodFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“[18] The open-label group improved by 92 points on this measure; in addition, the improvement shown by the openlabel placebo group exceeded that shown by the no-treatment group by 46 points.”
MethodInfluentialIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384 · cited 1×
“[7,8] It is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits.”
BackgroundBiological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,272
Self-citation
Research works printed but not linked: 1
- Vanner SJ Depew WT Paterson WG 2004 Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome and functional dyspepsia. Gut 53 666 72 · DOI · Paper page
Cited by
Items 101–200 of 897
Manchikanti, L., Cash, K. A., Pampati, V., Wargo, B. W., & Malla, Y. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/465 · Cited by 74
Widespread use of pure and impure placebo interventions by GPs in Germany
Meißner, K., Hofner, L., Fässler, M., & Linde, K. (2011) · Family Practice · doi:10.1093/fampra/cmr045 · Cited by 73
Clinical Use of Placebo Effects in Patients With Pain Disorders
Klinger, R., Stuhlreyer, J., Schwartz, M., Schmitz, J., & Colloca, L. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.015 · Cited by 88
“3 Open Label Placebos—There is encouraging evidence that OLPs in the treatment of patients with different pain disorders is effective (Carvalho et al., 2016; KamHansen et al., 2014; Kaptchuk et al., 2010).”
BackgroundOpen-label placebo clinical trials: is it the rationale, the interaction or the pill?
Blease, C., Bernstein, M. H., & Locher, C. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2019-111209 · Cited by 76
“6 If the presentation of a psychological rationale and positive framing are considered necessary to the intervention, then OLPs are vulnerable to comparable methodological hurdles arising in psychotherapy research where allegiance—and potential bias—plays a large role in outcomes.”
Elsenbruch, S., Schmid, J., Bäsler, M., Cesko, E., Schedlowski, M., & Benson, S. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01950.x · Cited by 69
Multicriteria benefit–risk assessment using network meta-analysis
van Valkenhoef, G., Tervonen, T., Zhao, J., de Brock, B., Hillege, H. L., & Postmus, D. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.09.005 · Cited by 75
“Recent research suggests that placebo may be effective even without deception [24] (in irritable bowel syndrome), so it may be worthwhile to explore this option for mildly depressed patients.”
BackgroundKhlevner, J., Park, Y., & Margolis, K. G. (2018) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2018.07.002 · Cited by 81
Spiegel, B. M. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.030 · Cited by 67
Pradeu, T., Lemoine, M., Khelfaoui, M., & Gingras, Y. (2021) · The British Journal for the Philosophy of Science · doi:10.1086/715518 · Cited by 101
Treatment of Functional Motor Disorders
Gelauff, J., Dreissen, Y. E. M., Tijssen, M. A. J., & Stone, J. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0286-5 · Cited by 68
Castelnuovo, G., Giusti, E. M., Manzoni, G. M., Saviola, D., Gabrielli, S., Lacerenza, M. R., Pietrabissa, G., Cattivelli, R., Spatola, C. A. M., Rossi, A. A., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00310 · Cited by 70
Locher, C., Gaab, J., & Blease, C. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.02317 · Cited by 65
“A second, nuanced and different use of the term comes under the label “openlabel placebos” (OLPs) (Blease, 2018b); here “placebo” refers to specific interventions (usually sugar pills) which are administered alongside other socio-emotional cues in the patient-practitioner encounter usually with the aim of eliciting sa…”
BackgroundManchikanti, L., Singh, V., Cash, K. A., Pampati, V., & Falco, F. J. E. (2014) · Pain Physician · doi:10.36076/ppj.2014/17/e61 · Cited by 80
van Tilburg, M. A. L., Palsson, O. S., Ringel, Y., & Whitehead, W. E. (2014) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2013.12.015 · Cited by 64
Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
Friesen, P., & Blease, C. R. (2018) · Journal of Medical Ethics · doi:10.1136/medethics-2018-104811 · Cited by 66
Nurko, S., Saps, M., Kossowsky, J., Zion, S. R., Lorenzo, C. D., Vaz, K. K. H., Hawthorne, K., Wu, R., Ciciora, S. L., Rosen, J. M., et al. (2022) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.5750 · Cited by 63
Self-citationShen, X., Xie, A., Li, Z., Jiang, C., Wu, J., Li, M., & Yue, X. (2024) · Foods · doi:10.3390/foods13010151 · Cited by 75
“A randomized clinical trial comparing the use of placebos to untreated IBS patients revealed that the use of placebos was significantly more likely to provide sufficient relief from symp-Foods toms [92].”
BackgroundQi, L.-Y., Yang, J., Yan, S., Tu, J., She, Y.-F., Li, Y., Chi, L.-L., Wu, B., & Liu, C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.48817 · Cited by 75
Go open: A plea for transparency in psychotherapy.
Gaab, J., Blease, C., Locher, C., & Gerger, H. (2016) · Psychology of Consciousness: Theory, Research, and Practice · doi:10.1037/cns0000063 · Cited by 60
Harnessing the Placebo Effect in Pediatric Migraine Clinic
Faria, V., Linnman, C., Lebel, A., & Borsook, D. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.06.040 · Cited by 61
“Being transparent about the possible benefits of the administered treatment enhances therapeutic expectations that in turn result in benefits during both pharmacological(32) and placebo treatments.(27,28) It has also been reported that expecting an inert treatment abolishes the beneficial effects of an analgesic drug.”
Manchikanti, L., Cash, K. A., Pampati, V., & Malla, Y. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.8069 · Cited by 55
“The effects of placebo, nocebo, Hawthorne effect, natural course of the disease which is not applicable in these chronic patients, and regression to mean have been extensively discussed in reference to placebo, nocebo, and pure, impure, and fake placeboes [120-123].”
BackgroundBallou, S., Kaptchuk, T. J., Hirsch, W., Nee, J., Iturrino, J., Hall, K. T., Kelley, J. M., Cheng, V., Kirsch, I., Jacobson, E., et al. (2017) · Trials · doi:10.1186/s13063-017-1964-x · Cited by 57
“To calculate power for our primary analyses, we used our previous pilot trial testing OLP in IBS [16].”
MethodResultSelf-citationPlacebo effects in allergen immunotherapy—An EAACI Task Force Position Paper
Pfaar, O., Agache, I. O., Bergmann, K., Bindslev‐Jensen, C., Bousquet, J. J., Creticos, P. S., Devillier, P., Durham, S. R., Hellings, P. W., Kaul, S., et al. (2021) · Allergy · doi:10.1111/all.14331 · Cited by 62
Open-label placebos for menopausal hot flushes: a randomized controlled trial
Pan, Y., Meister, R., Löwe, B., Kaptchuk, T. J., Bühling, K. J., & Nestoriuc, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-77255-z · Cited by 63
Self-citationPlacebo effects in osteoarthritis: implications for treatment and drug development
Neogi, T., & Colloca, L. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01021-4 · Cited by 64
Manchikanti, L., Pampati, V., Benyamin, R. M., & Boswell, M. V. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.10870 · Cited by 60
“Multiple issues related to placebo-controlled trials are based on ample evidence that inactive substances, when injected into active structures, invariably result in various types of clinical effects, as well as placebo and nocebo effects [3, 4, 36-50, 53, 58-75].”
BackgroundThe placebo effect in allergen‐specific immunotherapy trials
Narkus, A., Lehnigk, U., Häfner, D., Klinger, R., Pfaar, O., & Worm, M. (2013) · Clinical and Translational Allergy · doi:10.1186/2045-7022-3-42 · Cited by 58
“Because placebos can actually produce results comparable to specific drugs without deception [10,16], it is important to exploit the placebo effect by applying its mechanisms [17] and thus deliberately boosting the efficacy of treatments.”
BackgroundDo Manual Therapies Help Low Back Pain? A Comparative Effectiveness Meta-analysis
Menke, J. M. (2014) · Spine · doi:10.1097/brs.0000000000000230 · Cited by 55
Harji, D. P., Fernández, B., Boissieras, L., Berger, A., Capdepont, M., Zerbib, F., Rullier, É., & Denost, Q. (2021) · Colorectal Disease · doi:10.1111/codi.15812 · Cited by 54
“Placebo effects of treatment participation on improved QoL outcomes have been noted previously in other areas of colorectal surgery [38,39] and warrant further investigation in patients with LARS.”
BackgroundPlacebo, nocebo, and neuropathic pain
Vase, L., Skyt, I., & Hall, K. T. (2015) · Pain · doi:10.1097/j.pain.0000000000000445 · Cited by 66
Lessons from recent research about the placebo effect—from art to science
Brody, H., & Miller, F. G. (2011) · JAMA · doi:10.1001/jama.2011.1850 · Cited by 53
Self-citationEsch, T., & Stefano, G. B. (2022) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2022.913573 · Cited by 70
Against the “placebo effect”: A personal point of view
Moerman, D. E. (2013) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2013.01.005 · Cited by 55
The role of patient beliefs in open-label placebo effects.
Leibowitz, K. A., Hardebeck, E. J., Goyer, J. P., & Crum, A. J. (2019) · Health Psychology · doi:10.1037/hea0000751 · Cited by 59
“Compared with a no-treatment control group who had the same quantity and quality of interactions with the physician, participants who took the open-label placebo pills had significantly improved IBS symptoms at the end of the study period (Kaptchuk et al., 2010).”
InfluentialThe Emperor’s New Drugs: Medication and Placebo in the Treatment of Depression
Kirsch, I. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44519-8_16 · Cited by 63
Self-citationFlowers, K. M., Patton, M. E., Hruschak, V., Fields, K. G., Schwartz, E., Zeballos, J., Kang, J. D., Edwards, R. R., Kaptchuk, T. J., & Schreiber, K. L. (2021) · Pain · doi:10.1097/j.pain.0000000000002185 · Cited by 59
“Other studies have also demonstrated OLP benefits on a variety of symptoms, 20,49,53,61 including back pain, 20,58 and conditioned-placebo studies have shown successful conditioning of opioid effects in laboratory experiments, 3 exhibiting analgesic efficacy in the form of opioid dose reductions.”
Self-citationFunctional neurological disorder and placebo and nocebo effects: shared mechanisms
Fiorio, M., Braga, M., Marotta, A., Villa‐Sánchez, B., Edwards, M. J., Tinazzi, M., & Barbiani, D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00711-z · Cited by 70
Meister, R., Abbas, M., Antel, J., Peters, T., Pan, Y., Bingel, U., Nestoriuc, Y., & Hebebrand, J. (2018) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1244-7 · Cited by 55
A role for placebo therapy in psychogenic movement disorders
Rommelfanger, K. S. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.65 · Cited by 52
Neural Mechanisms of Placebo Anxiolysis
Meyer, B., Yuen, K. S. L., Ertl, M., Polomac, N., Mulert, C., Büchel, C., & Kalisch, R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4793-14.2015 · Cited by 55
The sweetest pill to swallow: How patient neurobiology can be harnessed to maximise placebo effects
Jubb, J., & Bensing, J. M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.09.006 · Cited by 63
Unanticipated Insights into Biomedicine from the Study of Acupuncture
MacPherson, H., Hammerschlag, R., Coeytaux, R. R., Davis, R. T., Harris, R. E., Kong, J., Langevin, H. M., Lao, L., Milley, R. J., Napadow, V., et al. (2016) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2015.0184 · Cited by 58
Spille, L., Fendel, J. C., Seuling, P. D., Göritz, A. S., & Schmidt, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-30362-z · Cited by 53
Clinical Research Methodology 1: Study Designs and Methodologic Sources of Error
Sessler, D. I., & Imrey, P. B. (2015) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000815 · Cited by 78
Brihi, J. E., Horne, R., & Faasse, K. (2018) · Annals of Behavioral Medicine · doi:10.1093/abm/kay011 · Cited by 58
Bishop, F. L., Jacobson, E., Shaw, J. R., & Kaptchuk, T. J. (2012) · Social Science & Medicine · doi:10.1016/j.socscimed.2011.11.020 · Cited by 53
“…is particularly important for open-label studies, such as another recent RCT that found that open-label (i.e., non-deceptive and nonconcealed) placebo treatment administered in a context of a persuasive rationale can elicit clinically significant placebo responses (Kaptchuk et al., 2010).”
Self-citationGreco, C. M., Yu, L., Johnston, K. L., Dodds, N. E., Morone, N. E., Glick, R. M., Schneider, M., Klem, M. L., McFarland, C. E., Lawrence, S. M., et al. (2015) · Quality of Life Research · doi:10.1007/s11136-015-1178-1 · Cited by 54
“Additionally, when given pills clearly marked ‘placebo,’ and told of potential mind–body benefits, 59 % of irritable bowel syndrome patients reported adequate improvement [13].”
The moral case for the clinical placebo
Gold, A., & Lichtenberg, P. (2013) · Journal of Medical Ethics · doi:10.1136/medethics-2012-101314 · Cited by 54
Benedetti, F., Frisaldi, E., & Shaibani, A. I. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-104536 · Cited by 62
Haas, J. W., Ongaro, G., Jacobson, E., Conboy, L. A., Nee, J. W., Iturrino, J., Rangan, V., Lembo, A. J., Kaptchuk, T. J., & Ballou, S. (2022) · BMC Psychology · doi:10.1186/s40359-022-00731-w · Cited by 50
“, honestly prescribed placebos (OLP) for irritable bowel syndrome (IBS) on top of their treatment as usual (TAU) they had significant and clinical meaningful improvement compared to the control group of TAU alone [10].”
BackgroundSelf-citationBishop, F. L., Aizlewood, L., & Adams, A. E. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101822 · Cited by 53
“[22–25] However, recent research confirms earlier suggestions that this dilemma might have shaky foundations: it might be possible to elicit clinically meaningful placebo effects in depression and irritable bowel syndrome by prescribing pure placebos openly without deceiving patients.[26,27] If these initial findings…”
BackgroundReevaluating the Placebo Effect in Medical Practice
Colloca, L., Jonas, W. B., Killen, J., Miller, F. G., & Shurtleff, D. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000177 · Cited by 46
“In fact, an open-label study showed that placebos induced improvement of symptoms in patients with Irritable Bowel Syndrome who were explicitly instructed to take placebos, described as pills without medication, with the purpose to evoke a placebo effect (Kaptchuk et al., 2010).”
BackgroundSelf-citationRoderigo, T., Benson, S., Schöls, M., Hetkamp, M., Schedlowski, M., Enck, P., & Elsenbruch, S. (2017) · Pain · doi:10.1097/j.pain.0000000000000940 · Cited by 47
“discomfort arising from the lower or upper gastrointestinal (GI) tract.(17,24,31,32) In contrast to placebo, nocebo effects remain poorly studied not only in the context of disturbed visceroception(17) but also in the broader somatic pain field,(1,11,49,60) but conceivably contribute to the reporting of adverse events…”
The principle of parity: the ‘placebo effect’ and physician communication
Blease, C. (2011) · Journal of Medical Ethics · doi:10.1136/medethics-2011-100177 · Cited by 52
“Indeed, recent (albeit limited) research seems to support the claim that placebos can work even when patients are informed of their usage.(3) In this paper, advancing on the recent work by Louhiala and Puustinen,(4) 5 I propose that the term ‘placebo effect’ be replaced in clinical contexts by the term ‘positive care…”
ResultBishop, F. L., Coghlan, B., Geraghty, A. W., Everitt, H., Little, P., Holmes, M. M., Seretis, D., & Lewith, G. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015516 · Cited by 46
“This taxonomy can guide two important and related applied research agendas: (1) to understand the components of placebo effects in clinical settings(46) 67–70 and (2) to ethically harness evidence-based placebo effects to benefit patients.(14) 15 71 We hope future studies might draw on the taxonomy to fully describe t…”
MethodTreating ADHD With Suggestion: Neurofeedback and Placebo Therapeutics
Thibault, R. T., Veissière, S. P. L., Olson, J. A., & Raz, A. (2018) · Journal of Attention Disorders · doi:10.1177/1087054718770012 · Cited by 55
“Researchers have reproduced this finding in several conditions, including irritable bowel syndrome, chronic pain, and depression (Kaptchuk et al., 2010; Kelley, Kaptchuk, Cusin, Lipkin, & Fava, 2012; Schafer, Colloca, & Wager, 2015).”
BackgroundBuergler, S., Sezer, D., Gaab, J., & Locher, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-39123-4 · Cited by 51
Placebo responses and placebo effects in functional bowel disorders
Enck, P., Horing, B., Weimer, K., & Klosterhalfen, S. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32834bb951 · Cited by 45
Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome
Thijssen, A. Y., Clemens, C. H. M., Vankerckhoven, V., Goossens, H., Jonkers, D. M. A. E., & Masclee, A. A. M. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000484 · Cited by 45
Deceptive and Nondeceptive Placebos to Reduce Pain: An Experimental Study in Healthy Individuals
Κube, T., Rief, W., Vivell, M.-B., Schäfer, N. L., Vermillion, T., Körfer, K., & Glombiewski, J. A. (2019) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000781 · Cited by 50
Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome
Shah, E. D., & Pimentel, M. (2014) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2014.20.2.163 · Cited by 57
“166 Journal of Neurogastroenterology and Motility placebo against a no-treatment arm in IBS patients, patients obtained statistically significant benefit on placebo therapy.(36) Despite these findings, reproducibility of placebo analgesia re-”
BackgroundThe Placebo Phenomenon: Implications for the Ethics of Shared Decision-Making
Brody, H. A., Colloca, L., & Miller, F. G. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1977-1 · Cited by 45
Self-citationClinical Research Methodology 3: Randomized Controlled Trials
Sessler, D. I., & Imrey, P. B. (2015) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000862 · Cited by 46
“, parallel group, factorial); (2) important changes after starting enrollment; (3) eligibility criteria; (4) interventions, with sufficient detail to allow replication; (5) completely defined prespecified primary and secondary outcomes; (6) interim analyses, stopping rules, and sample size determination and justificat…”
BackgroundThe Ethics of Placebo Effects in Clinical Practice and Research
Annoni, M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.031 · Cited by 52
Schaefer, M., Denke, C., Harke, R., Olk, N., Erkovan, M., & Enge, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-49466-6 · Cited by 44
Placebo and Psychotherapy: Differences, Similarities, and Implications
Gaab, J., Locher, C., & Blease, C. R. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.01.013 · Cited by 55
Should we reconsider the routine use of placebo controls in clinical research?
Avins, A. L., Cherkin, D. C., Sherman, K. J., Goldberg, H., & Pressman, A. (2012) · Trials · doi:10.1186/1745-6215-13-44 · Cited by 43
“However, many authorities contend that the deliberate use of placebos runs counter to modern clinical ethics since it requires deceiving patients by leading them to believe that the placebo has specific biologic activity that it does not possess [10-12] (though recent data suggest that deception might not be essential…”
BackgroundPlacebo Effects and the Ethics of Therapeutic Communication: A Pragmatic Perspective
Annoni, M., & Miller, F. G. (2016) · Kennedy Institute of Ethics journal · doi:10.1353/ken.2016.0004 · Cited by 58
“As part of the disclosure procedure, the participants in this study were presented with the following script: “placebo pills, something like sugar pills, have been shown in rigorous clinical testing to produce significant mind-body self-healing processes” (Kaptchuk et al. 2010, 2).”
BackgroundMethodInfluentialSelf-citationNascimento, A. F., Gaab, J., Kirsch, I., Kossowsky, J., Meyer, A. H., & Locher, C. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032868 · Cited by 43
Self-citationAffect and emotions in placebo and nocebo effects: What do we know so far?
Geers, A. L., Faasse, K., Guevarra, D. A., Clemens, K. S., Helfer, S. G., & Colagiuri, B. (2020) · Social and Personality Psychology Compass · doi:10.1111/spc3.12575 · Cited by 60
It's All in Your Head: Reinforcing the Placebo Response With tDCS
Schambra, H. M., Bikson, M., Wager, T. D., DosSantos, M. F. H., & DaSilva, A. F. M. (2014) · Brain stimulation · doi:10.1016/j.brs.2014.04.002 · Cited by 49
“Could placebo administration, given even explicitly in a clinical psychosocial context [20], be used to create a neural “training signal” to be reinforced by tDCS? We hypothesize that placeboactivated brain regions, particular to the pathopsychology being ameliorated, would be the physiologic substrate of tDCS neuromo…”
BackgroundHendricks, P. S., & Leventhal, A. M. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3169-7 · Cited by 47
“For example, in a randomized clinical trial of treatment for irritable bowel syndrome, participants receiving open-label placebo pills demonstrated significantly greater symptom improvement than no-treatment controls (Kaptchuk et al. 2010).”
The power and value of placebo and nocebo in painful osteoarthritis
Dieppe, P. A., Goldingay, S., & Greville-Harris, M. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.06.007 · Cited by 51
“given have no active ingredient that should make any difference, have been successfully carried out [54], and the participants’ symptoms have improved, indicating that we could give people with OA a placebo without deception, and study their responses (both positive and negative) using a variety of clinical, biochemic…”
MethodAli, A., Weiss, T. R., McKee, D., Scherban, A., Khan, S., Fields, M. R., Apollo, D., & Mehal, W. Z. (2017) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2017-000164 · Cited by 42
“These findings reject the null hypothesis and show that a diet guided by leucocyte activation testing results in demonstrable clinical improvement in IBS.”
BackgroundMethodInfluentialOpen-label placebo for chronic low back pain: a 5-year follow-up
Carvalho, C., Pais, M., Cunha, L., Rebouta, P., Kaptchuk, T. J., & Kirsch, I. (2020) · Pain · doi:10.1097/j.pain.0000000000002162 · Cited by 43
Self-citationThe Underestimated Significance of Conditioning in Placebo Hypoalgesia and Nocebo Hyperalgesia
Bräscher, A., Witthöft, M., & Becker, S. (2018) · Pain Research and Management · doi:10.1155/2018/6841985 · Cited by 48
“Typically, open-label placebo studies try to boost expectation of a positive effect despite openly administering an inert substance [51, 52].”
BackgroundChen, A. T., Shrestha, S., Collins, J. E., Sullivan, J., Losina, E., & Katz, J. N. (2020) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.05.007 · Cited by 44
Kleine‐Borgmann, J., Schmidt, K., Billinger, M., Forkmann, K., Wiech, K., & Bingel, U. (2021) · Scientific Reports · doi:10.1038/s41598-021-81502-2 · Cited by 42
Manchikanti, L., Cash, K. A., McManus, C. D., Pampati, V., & Benyamin, R. M. (2014) · Pain Physician · doi:10.36076/ppj.2014/17/e327 · Cited by 42
Integrative oncology: really the best of both worlds?
Gorski, D. H. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3822 · Cited by 45
Henrich, J. F., Knittle, K. P., Gucht, V. D., Warren, S., Dombrowski, S. U., & Maes, S. (2014) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2014.12.009 · Cited by 44
“[77] Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al.”
BackgroundKrieger‐Grübel, C., Hutter, S., Hiestand, M., Brenner, I., Güsewell, S., & Borovicka, J. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.09.020 · Cited by 47
Electroconvulsive therapy, the placebo effect and informed consent
Blease, C. (2012) · Journal of Medical Ethics · doi:10.1136/medethics-2012-100955 · Cited by 41
Freed, B., Williams, B., Situ, X., Landsman, V., Kim, J., Moroz, A., Bang, H., & Park, J. J. (2021) · Clinical Trials · doi:10.1177/1740774520984870 · Cited by 40
“Our finding may add more support to accumulating evidence toward potential benefits of placebo and sham treatments with complexity in research and clinical contexts/settings.(57,58) Second, our study conveys some methodologic strengths: back pain is an ideal medical condition to study our aims because multiple treatme…”
ResultParental Attitudes About Placebo Use in Children
Faria, V., Kossowsky, J., Petkov, M. P., Kaptchuk, T. J., Kirsch, I., Lebel, A., & Borsook, D. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.10.018 · Cited by 39
Self-citationBlease, C. R. (2019) · Australian Journal of General Practice · doi:10.31128/ajgp-05-19-4939 · Cited by 55
Nitzan, U., Carmeli, G., Chalamish, Y., Braw, Y., Kirsch, I., Shefet, D., Krieger, I., Mendlovic, S., Bloch, Y., & Lichtenberg, P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.077 · Cited by 38
Self-citationA Comparison of Deceptive and Non-Deceptive Placebo Analgesia: Efficacy and Ethical Consequences
Mundt, J. M., Roditi, D., & Robinson, M. E. (2016) · Annals of Behavioral Medicine · doi:10.1007/s12160-016-9854-0 · Cited by 38
“A study of patients with irritable bowel syndrome [12] compared an open-label placebo pill to no treatment, but this study did not include a conditioning procedure to enhance placebo efficacy and did not include a deceptive placebo condition, which would allow for a comparison of the efficacy of deceptive and non-dece…”
BackgroundEetemadi, A., & Tagkopoulos, I. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2020.12.041 · Cited by 46
“The high threshold of 150 is reasonable since the reported mean plus standard deviation of DIBS-SSS for a placebo treatment can range from 124 to 162, [11,12] and therefore a “High” response is unlikely to be associated with a placebo effect.”
BackgroundOpen-label nondeceptive placebo analgesia is blocked by the opioid antagonist naloxone
Benedetti, F., Shaibani, A. I., Arduino, C., & Thoen, W. (2022) · Pain · doi:10.1097/j.pain.0000000000002791 · Cited by 38
Ortiz, R., Hull, S. C., & Colloca, L. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-011012 · Cited by 39
“However, recent clinical results show that honest descriptions do not necessarily preclude the placebo effect.(17) Also, individuals were more likely to identify trust as related to their own decision, compared to honesty as more relevant to the decision for others.”
ResultPlacebo Effects: Historical and Modern Evaluation
Finniss, D. G. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.010 · Cited by 45
Overcoming disagreement: a roadmap for placebo studies
Blease, C., & Annoni, M. (2019) · Biology & Philosophy · doi:10.1007/s10539-019-9671-5 · Cited by 39
Saunders, B., Saito, T., Klosterhoff, R. R., de Oliveira, L. F., Barreto, G., Perim, P., Pinto, A. J., Lima, F. R., Pinto, A. L. D. S., & Gualano, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222982 · Cited by 40
“The 39% positive response rate to the open-placebo intervention in this study is lower than the 59% relief rate shown for irritable bowel syndrome [7] or 74% improvement in fatigue scores in cancer survivors [12].”
BackgroundResultInfluentialBernstein, M. H., Locher, C., Stewart‐Ferrer, S., Buergler, S., DesRoches, C. M., Dossett, M. L., Miller, F. G., Grose, D., & Blease, C. (2020) · British Journal of Health Psychology · doi:10.1111/bjhp.12429 · Cited by 50
“…openlabel placebos for irritable bowel syndrome, cancer-related fatigue, and chronic lower back pain (Carvalho et al., 2016; Hoenemeyer, Kaptchuk, Mehta, & Fontaine, 2018; Kaptchuk et al., 2010) have been published in medical journals and widely disseminated across major international news outlets.”
BackgroundMethodSelf-citationCognitive Factors Mediate Placebo Responses in Patients with House Dust Mite Allergy
Vits, S., Cesko, E., Benson, S., Rueckert, A., Hillen, U., Schadendorf, D., & Schedlowski, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079576 · Cited by 35
“Also, an interesting approach with regard to the applicability of placebos in clinical routine for the benefit of the patient, is the administration of open-label placebo [43,44], which remains to be tested for its effectiveness in allergy.”
BackgroundOpen-label Placebos for Wound Healing: A Randomized Controlled Trial
Mathur, A., Jarrett, P., Broadbent, E., & Petrie, K. J. (2018) · Annals of Behavioral Medicine · doi:10.1093/abm/kax057 · Cited by 35
Tan, K., Wells, C. I., Dinning, P. G., Bissett, I. P., & O’Grady, G. (2019) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13092 · Cited by 36
Listening to Placebo in Clinical Trials for Female Sexual Dysfunction
Bradford, A. M. (2013) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02941.x · Cited by 36
Dutile, S., Kaptchuk, T. J., & Wechsler, M. E. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0456-2 · Cited by 38
Self-citation
Metadata
- Authors
- Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- National Institutes of Health (US)
- University of Hull (GB)
- Corresponding author
- Kaptchuk, Ted J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-22
- Volume
- 5
- Issue
- 12
- Pages
- e15591
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3008733
- OpenAlex
- W2105330971
- Semantic Scholar
- 3d8aac4fba0e556c2d0898ad83cd3df11576e90c
- Cited by
- 900
- References
- 43
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 48 · 2023: 56 · 2022: 55 · 2021: 67 · 2020: 72 · 2019: 55 · 2018: 97 · 2017: 48 · 2016: 55 · 2015: 55 · 2014: 65 · 2013: 48 · 2012: 58
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Bernard Osher Foundation
- National Institutes of Health (5r01at000402-04)
- Japan Society for the Promotion of Science (13J11021)
- National Center for Complementary and Alternative Medicine
- National Center for Complementary and Integrative Health (R01AT004662, K24AT004095, R01 AT00402-01)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
- Keywords
- irritable bowel syndrome, placebo effect, open-label placebo, symptom severity, quality of life, patient-provider interaction, informed consent
- MeSH terms
- Adult, Female, Humans, Deception, Male, Middle Aged, Placebos, Time Factors, Treatment Outcome, Patient Satisfaction, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

